Cyclo Therapeutics, Inc.
CYTHDelisted Mar 26, 2025- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000922247
Cyclo Therapeutics, Inc. was delisted on Mar 26, 2025; its insiders filed their last Form 4 on Mar 3, 2025; 22 institutions reported holding it in 13F filings for Q4 2024, worth $1.33M in total; no superinvestor held it.
13F holders, Q4 2023
Institutional positions in Cyclo Therapeutics, Inc. as of Dec 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 23
- +6 vs. Q3 2023
- Shares held
- 1.30M
- +819.1K (+170.3%) vs. Q3 2023
- Total value
- $2.06M
- +$1.38M (+202.1%) vs. Q3 2023
- New holders
- 9
- 7 more added
- Sold out
- 3
- 3 more reduced
Compare with Q3 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CYTH on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 22 | $1.33M |
| Q3 2024 | 19 | $1.80M |
| Q2 2024 | 22 | $2.84M |
| Q1 2024 | 22 | $3.01M |
| Q4 2023 | 23 | $2.06M |
| Q3 2023 | 17 | $682.7K |
| Q2 2023 | 14 | $725.2K |
| Q1 2023 | 16 | $820.2K |
| Q4 2022 | 15 | $1.83M |
| Q3 2022 | 12 | $768.0K |
| Q2 2022 | 13 | $794.0K |
| Q1 2022 | 13 | $1.38M |
| Q4 2021 | 15 | $1.71M |
| Q3 2021 | 13 | $2.23M |
| Q2 2021 | 12 | $2.70M |
| Q1 2021 | 9 | $585.0K |
Institutions, Q4 2023
Shares, value and share of portfolio for each institution holding Cyclo Therapeutics, Inc.; share changes are against Q3 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Founders Fund V Management, LLC | 480,708 | $764.3K | 80.75% | +480,708 | New |
| Vanguard Group Inc | 355,223 | $564.8K | 0.00% | +73,196+26.0% | Added |
| Geode Capital Management, LLC | 152,077 | $241.9K | 0.00% | +51,570+51.3% | Added |
| Founders Fund VI Management, LLC | 110,023 | $174.9K | 1.37% | +110,023 | New |
| Citadel Advisors LLC | 54,018 | $85.9K | 0.00% | +39,881+282.1% | Added |
| BlackRock Inc. | 48,444 | $77.0K | 0.00% | +48,082+13,282.3% | Added |
| State Street Corp | 39,525 | $62.8K | 0.00% | +7,325+22.7% | Added |
| Wealth Enhancement Advisory Services, LLC | 18,513 | $29.4K | 0.00% | +18,513 | New |
| Northern Trust Corp | 17,453 | $27.8K | 0.00% | +860+5.2% | Added |
| XTX Topco Ltd | 10,696 | $17.0K | 0.00% | −2,204−17.1% | Reduced |
| Tower Research Capital LLC (TRC) | 5,871 | $9.34K | 0.00% | −896−13.2% | Reduced |
| Wells Fargo & Company | 2,386 | $3.79K | 0.00% | +34+1.4% | Added |
| Royal Bank of Canada | 746 | $1.00K | 0.00% | 00.0% | Unchanged |
| Advisor Group Holdings, Inc. | 600 | $954 | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 413 | $657 | 0.00% | 00.0% | Unchanged |
| Princeton Global Asset Management LLC | 300 | $477 | 0.00% | 00.0% | Unchanged |
| Qube Research & Technologies Ltd | 121 | $192 | 0.00% | +121 | New |
| New York State Common Retirement Fund | 113 | $180 | 0.00% | +113 | New |
| Steward Partners Investment Advisory, LLC | 90 | $143 | 0.00% | +90 | New |
| JPMorgan Chase & Co | 18 | $29 | 0.00% | −222−92.5% | Reduced |
| Bank of America Corp | 14 | $22 | 0.00% | +14 | New |
| Simplex Trading, LLC | 200 | $0 | 0.00% | +200 | New |
| Acadian Asset Management LLC | 2,527 | – | – | +2,527 | New |
| Virtu Financial LLC | 0 | $0 | 0.00% | −10,732−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −88−100.0% | Sold out |
| IFP Advisors, Inc | 0 | $0 | 0.00% | −13−100.0% | Sold out |